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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
We aim to determine if the use of HFNC is better than other forms of non-invasive therapy in paediatric patients who require respiratory
support.
B A C K G R O U N D
Description of the condition
Respiratory support is central to the care of critically ill children.
Support may be needed due to underlying disease processes such
as respiratory infections or pneumonia, neuromuscular disorders,
cardiac conditions or failure, and other mechanisms such as up-
per airway obstruction, trauma and injury, or post-surgical inter-
ventions. Respiratory support can be delivered non-invasively in
the form of oxygen therapy or continuous positive airway pressure
(CPAP) or invasively via mechanical ventilation. Children with
significant respiratory distress and hypoxaemia often require the
latter. This may result in various forms of trauma to the lungs
and airways, collectively known as ventilator induced lung injury
(VILI) (Dahlem 2003; The ARDS Network 2000).
While VILI is the major concern with intubation and mechanical
ventilation, there are other effects on the body that need to be con-
sidered. The increased use of sedative drugs may lead to neuropa-
thy or myopathy, which can increase recovery time. In turn there
may be the need for cardiovascular support in the form of drug
infusions to maintain blood pressure. All of these factors increase
the costs of the care provided to the child. Non-invasive methods
of ventilation are an ideal method of providing respiratory sup-
port without the need for intubation and may avoid some of the
additional harm associated with positive pressure ventilation.
Non-invasive ventilation can be as simple as oxygen therapy deliv-
ered via a face mask, nasal cannula or head box through to devices
deliveringCPAP via the face andmask interface or nasopharyngeal
tubes, with pressure generated by a dedicated driver or water col-
umn (that is bubble CPAP) (Frey 2001; Frey 2003; Klein 1986).
Those devices delivering CPAP can reduce the work of breathing
and improve functional residual capacity, potentially avoiding in-
tubation, reducing VILI, and preventing other possible causes of
harm (Reid 1984; Thorsteinsson 2002).
A disadvantage of this method of delivery is that it is cumber-
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some and the masks and tubes used are poorly tolerated by young
children and infants (Yong 2005). This can make the delivery of
CPAP variable thereby resulting in ineffective ventilation. Having
a system that can deliver CPAP and be comfortable and well toler-
ated by children is an important consideration in providing non-
invasive respiratory support.
Description of the intervention
High flow nasal cannula (HFNC) therapy has recently been in-
troduced to a range of patients from preterm infants to adults,
addressing the need for a simple, effective method of providing
respiratory support (Campbell 2006;McGinley 2009;McKiernan
2009; Shoemaker 2007). It has an advantage over simple oxygen
therapy in that the gas mixture can be heated and humidified,
thereby reducing damage to upper airwaymucosa, and the concen-
tration of inspired oxygen can also be titrated as required. This can
prevent inflammatory reactions and the naso-pulmonary bron-
choconstrictor reflex triggered by cold, dry air (Spentzas 2009).
It has been shown that the delivery of nasal air at high flow rates
may cause incidental delivery of CPAP (Dysart 2009; Spence
2007; Wilkinson 2008). The effects of this are yet to be fully un-
derstood. It may be that the high flow flushes the dead space of the
nasopharyngeal cavity resulting in alveolar ventilation as a greater
fraction of minute ventilation. It may also assist in the washout
of carbon dioxide, which may then reduce apnoeas secondary to
hypercapnia and improve ventilation (Dysart 2009). High flow
rates may also provide an amount of positive pressure and thereby
overcome upper airway obstruction, again improving ventilation
(McGinley 2009).
The amount of CPAP generated depends on the flow delivered
relative to the size of the patient, the size of the nasal cannula
used, and the potential leak around the nasal cannula (Kubicka
2008; Lampland 2009; Sreenan 2001). Three retrospective studies
assessing HFNC therapy have demonstrated that overall ventilator
days were significantly decreased after the introduction of this
therapy when compared to retrospective historical control groups
(McKiernan 2009; Schibler 2011; Shoemaker 2007).
HFNC therapy has also been reported to be better tolerated by
the patient than other forms of non-invasive ventilation (Roca
2010). This can reduce the need for sedation that is required to
help tolerate more invasive or uncomfortable forms of respiratory
support.
Why it is important to do this review
HFNC therapy is an emerging treatment option for the respiratory
support of children, especially in the intensive care unit. To date,
most of the findings have been from neonatal and adult studies,
with little clinical experience reported in the paediatric population
(McKiernan 2009). The Cochrane review on high flow nasal can-
nula from the Cochrane Neonatal Group concluded that there is
insufficient evidence to determine HFNC effectiveness and that
more research is needed (Wilkinson 2011). At present there is a
protocol for the systematic review assessing HFNC effectiveness
in the adult population, which is in progress with the Cochrane
Anaesthesia Group (Corley in process). There is also a protocol
with the Cochrane Acute Respiratory Infections Group assessing
HFNC therapy for infants with bronchiolitis (Beggs 2012). This
review differs in that it covers a wider age range and more diverse
pathophysiologies.
It is necessary to assess the use of this therapy amongst the paedi-
atric population as there are potential risks associated with its use.
Neonatal studies have described scalp emphysema and pneumo-
cephalus as potential risks, along with nasal mucosal trauma and
bleeding (Jasin 2008; Kopelman 2003). There is also concern that
this therapy in the neonatal population provides unpredictable,
high pressures that could damage the preterm lung (Lampland
2009). These risks need to be assessed in the paediatric popula-
tion.
HFNC has the potential to improve outcomes in critically ill chil-
dren. It is readily applied and is not resource or cost intensive.
Staff can easily be trained in the application of HFNC and in the
care of children using this therapy. It may reduce the incidence of
intubation in paediatrics and may reduce the length of intubation
as HFNC holds potential as an adjunct between extubation and
low flow nasal prong oxygen delivery. The potential also exists that
children requiring this therapy may be cared for outside of the
paediatric intensive care unit (PICU).
O B J E C T I V E S
We aim to determine if the use of HFNC is better than other
forms of non-invasive therapy in paediatric patients who require
respiratory support.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include prospective, randomized controlled trials (RCTs)
and quasi-randomized studies.
Types of participants
We will include paediatric participants aged from four weeks cor-
rected age to 16 years requiring respiratory support.
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Types of interventions
For the purposes of this review, we will define high flow nasal
oxygen as the delivery of heated, humidified oxygen or blended
oxygen with air via a nasal cannula at flow rates of greater than
2 L/minute. HFNC will be compared with other means of non-
invasive respiratory support, such as cot, hood or tent oxygen; low
flow nasal cannula (flow rates equal to or less than 2 L/min); and
continuous positive airway pressure (CPAP).
Types of outcome measures
Primary outcomes
1. Hospital mortality
2. Intubation rate
3. Treatment failure (defined by the use of additional respiratory
support)
Secondary outcomes
1. Duration of any form of respiratory support in hours (mechan-
ical ventilation, non-invasive ventilation, high flow nasal cannula)
2. Length of stay in days in hospital
3. Clinical severity score
4. Length of PICU stay in days
5. Complications:
• air leaks (pneumothorax, pneumomediastinum,
pneumopericardium or pulmonary interstitial emphysema
(PIE)) reported either individually or as a composite outcome
• nasal trauma (defined as erythema or erosion of the nasal
mucosa, nares or septum assessed by a blinded observer)
• nosocomial sepsis (defined as positive blood or
cerebrospinal fluid (CSF) cultures)
• barotrauma
• gastrointestinal distention
Additional outcomes measured in trials will be added as secondary
outcomes following the literature search.
Search methods for identification of studies
Electronic searches
We will obtain all relevant studies irrespective of language or pub-
lication status (published, unpublished, in press, and in progress)
using the following methods. We will apply no limits in terms of
language or year of publication.
We will search the current issue of the Cochrane Central Register
of Controlled Trials (CENTRAL) (The Cochrane Library); MED-
LINE via Ovid SP (January 1966 to date); EMBASE via Ovid
SP (January 1980 to date); CINAHL via EBSCO Host (1982 to
date); LILACS via the BIREME interface (1982 to date).
We will search electronic databases of higher degree theses for rele-
vant unpublished trials: Index to Theses (1950 to date), Australian
Digital Theses Program (1997 to date) and Proquest Digital Dis-
sertations (1980 to date).
We will combine our MEDLINE search strategy with the
Cochrane highly sensitive search strategy for identifying random-
ized controlled trials (RCTs) as suggested in the Cochrane hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
will adopt the MEDLINE search strategy (see Appendix 1) for
searching in all other databases.
For ongoing trials, we will search the Meta Register of Controlled
Trials (http://www.controlledtrials.com/) and the National Re-
search Register (http://clinicaltrials.gov/).
Searching other resources
We will handsearch citations from included studies.
We will not exclude studies on the basis of language.
We will contact authors known in the field to determine if unpub-
lished work is available.
Data collection and analysis
Selection of studies
Six authors ( SM, JJC, FB, JH, AS, KG) will undertake the review.
We will use the search strategy described to obtain titles and ab-
stracts of studies that may be relevant to the review. Two authors
(SM and JJC) will independently perform this screening. We will
discard studies that are not applicable, and the reason for each
trial that is excluded will be documented. We will resolve disagree-
ments by consulting with a third author (FB), who will decide on
inclusion or not.
We will compile a list of eligible trials, with a unique identifier,
on a form for eligible trials contained within the data extraction
form (see Appendix 2).
Data extraction and management
We will adapt the standardized Cochrane Anasthesia Review
Group (CARG) data extraction form (Appendix 2) to capture rel-
evant data specific to this review. We (SM and JJC) will use this
form independently to extract and collect data from the relevant
studies. We (SM and JJC) will resolve any discrepancies in the data
extracted by discussion.
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Assessment of risk of bias in included studies
Two authors (SM and JJC) will independently assess the method-
ological quality of the eligible trials. Any disagreements will be
resolved by a third author (FB). We will include a risk of bias table
as recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). The judgements ’low risk’, ’high
risk’ and ’unclear risk’ will be used in the table to determine bias.
SMwill enter the data into the Reviewmanager Software (RevMan
5.1) with verification of data entry conducted independently. The
following domains will be assessed.
1.Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel, and outcome assessors.
4. Intention-to-treat analysis.
We will use pre-defined criteria for treatment failure (switching to
an alternative respiratory support modality) and intubation.
Measures of treatment effect
We will summarize trials that meet the inclusion criteria in tables
to allow for comparison of characteristics and quality. Excluded
studieswill be tabulatedwith the reason for exclusiondocumented.
For dichotomous outcome data, such as mortality, we will use risk
ratio (RR) to determine effect. It will be displayed on a table as
’number with event’ and ’number without event’. For continuous
data we will collect the mean and standard deviation and display
it on a table. If different scales are used to measure continuous
data across trials wewill calculate the standardizedmean difference
(SMD) to determine treatment effect.
We will analyse outcomes from comparable trials with 95% con-
fidence intervals (CI) to estimate each trial’s treatment effect. We
will compare the results graphically using forest plots, with risk
ratio (RR) as the point estimate for dichotomous outcomes and
mean difference (MD) as the point estimate for continuous out-
comes.
Dealing with missing data
We will contact the corresponding author of the study to source
missing data. If the corresponding author does not respond, or if
it is not possible to find them, then we will include the trial in
question in the review butwewill analyse the effects of its inclusion
or exclusion on the overall results as part of the sensitivity analysis.
Assessment of heterogeneity
We will analyse heterogeneity using the Chi2 test on N-1 degrees
of freedom, with an alpha of 0.1 used for statistical significance,
and with the I2 statistic (Higgins 2011). I2 values of 25%, 50%
and 75% correspond to low, medium and high levels of hetero-
geneity, respectively. We will set an I2 threshold of greater than
50% to indicate a substantial variation across trials due to hetero-
geneity. We will use a fixed-effect model if we find insignificant
heterogeneity between trials. We will use a random-effects model
if significant heterogeneity exists between trials (Higgins 2011).
Wewill test for homogeneity between trials for each outcomeusing
the Cochran’s Q statistic, with P less than or equal to 0.10.
We will assess the clinical diversity (clinical heterogeneity) and
methodological diversity (risk of bias assessment) of the included
studies. We will undertake subgroup analysis to examine possible
clinical variability when the I2 statistic is less than 50% but het-
erogeneity remains statistically significant.
We will analyse outcome data from trial populations rather than
individuals in order to explain possible sources of variability (
Higgins 2011).
Assessment of reporting biases
We will assess publication bias or small study effects by preparing
a funnel plot. We will test for funnel plot asymmetry if there are
greater than 10 studies included in the meta-analysis.
Data synthesis
We will review the summary tables of included trials to identify
clinical heterogeneity amongst trials. If there are two or more ran-
domized trials with comparable populations undergoing similar
interventions, we will do a meta-analysis with a random-effects
model using RevMan 5.1.
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analysis to explore possible sources of
heterogeneity (for example participants, interventions). Hetero-
geneity among participants could be related to age, corrected ges-
tational age and underlying pathophysiological condition. Het-
erogeneity in treatment could be related to the amount of flow
delivered in relation to body weight.We will explore the impact of
differing flow rates with a subgroup analysis. We will tabulate and
assess adverse effects with descriptive techniques as they are likely
to be different for the various subgroups. Where possible, we will
calculate the RR with 95% CI for each adverse effect. We will use
a narrative summary of findings when there is clear evidence of
heterogeneity amongst trials (Sutton 2008).
Wewill examine differences in populations based on the following.
1. Age (corrected).
2. Pathophysiology, as follows:
• type 1 respiratory failure;
• type 2 respiratory failure;
• parenchymal lung disease;
• neuromuscular disorders;
• respiratory drive;
• airway obstruction;
• preterm birth.
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Sensitivity analysis
We will perform a sensitivity analysis, exploring the causes of het-
erogeneity and the robustness of results if there is an adequate
number of studies. We will perform sensitivity analysis of trials
with low-risk of bias versus high-risk of bias. We will compare
random-effects model and fixed-effect model estimates for each
outcome variable.
Summary of findings
Wewill use the principles of the GRADE system (Guyatt 2008) to
assess the quality of the body of evidence associated with specific
outcomes: mortality, intubation, failure of treatment or escalation
to non-invasive ventilation, length of PICU stay, length of time
on any form of respiratory support, oxygenation and respiratory
assessment tools in our review and construct a summary of findings
(SoF) table using the GRADE software. The GRADE approach
appraises the quality of a body of evidence based on the extent to
which one can be confident that an estimate of effect or association
reflects the item being assessed. The quality of a body of evidence
considers, within a study, the risk of bias (methodologic quality),
the directness of the evidence, heterogeneity of the data, precision
of effect estimates and risk of publication bias (Guyatt 2008).
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A P P E N D I C E S
Appendix 1. Search strategy for MEDLINE (Ovid SP)
1. (exp Oxygen Inhalation Therapy/ and intubation rates*.af.) or (high flow adj3 (nasal or prong or cannula)).mp. or (nasal adj3
oxygen).mp.
2. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or
trial.ab. or groups.ab.) not (animals not (humans and animals)).sh.
3. 1 and 2
Appendix 2. Data extraction form
Review title or ID
Study ID (surname of first author and year first full report of study was published e.g. Smith 2001)
Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies)
Notes:
1. General Information
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Date form completed (dd/mm/yyyy)
Name/ID of person extracting data
Report title
(title of paper/ abstract/ report that data are extracted from)
Report ID
(ID for this paper/ abstract/ report)
Reference details
Report author contact details
Publication type
(e.g. full report, abstract, letter)
Study funding sources
(including role of funders)
Possible conflicts of interest
(for study authors)
Notes:
2. Study Eligibility
Study Charac-
teristics
Eligibility criteria
(Insert eligibility criteria for each
characteristic as defined in the Pro-
tocol)
Yes No Unclear Location in text
(pg & ¶/fig/table)
Type of study Randomized Controlled Trial
Controlled Clinical Trial
(quasi-randomized trial)
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(Continued)
Participants Paediatric patients aged from 4
weeks corrected age to 16 years
Types of inter-
vention High flow nasal Oxygen(heated/
humidified, flow >2lt/kg/min)
Comparator: non invasive respi-
ratory support such as cot/tent/
hood, low flow oxygen or CPAP
Types of out-
come measures
Hospital mortality; intubation
rate; treatment failure.
Secondary: duration of any form
of respiratory support; length
of hospital stay; clinical severity
score; length of PICU stay; com-
plications- air leak, nasal trauma,
nosocomial sepsis, barotrauma,
gastrointestinal distention
INCLUDE EXCLUDE
Reason for ex-
clusion
Notes:
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW
3. Methods
Descriptions as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
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(Continued)
Aim of study
Design (e.g. parallel, crossover,
cluster)
Unit of allocation
(by individuals, cluster/ groups or
body parts)
Start date
End date
Total study duration
Ethical approval needed/ ob-
tained for study Yes No Unclear
Notes:
4. Risk of Bias assessment
See Chapter 8 of the Cochrane Handbook (Higgins 2011)
Domain Risk of bias Support for judgement Location in text
(pg & ¶/fig/table)
Low risk High risk Unclear
Random sequence
generation
(selection bias)
Allocation
concealment
(selection bias)
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(Continued)
Blinding of partic-
ipants and person-
nel
(performance bias)
Outcome group: All/
(if required) Outcome group:
Blinding of out-
come assessment
(detection bias)
Outcome group: All/
(if required) Outcome group:
Incomplete
outcome data
(attrition bias)
Selective outcome
reporting?
(reporting bias)
Other bias
Notes:
5. Participants
Provide overall data and, if available, comparative data for each intervention or comparison group.
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Total no. randomized
(or total pop. at start of study for NRCTs)
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(Continued)
Clusters
(if applicable, no., type, no. people per cluster)
Withdrawals and exclusions
(if not provided below by outcome)
Age
Sex
Severity of illness
Co-morbidities
Other treatment received (additional to
study intervention)
Subgroups measured
Subgroups reported
Notes:
6. Intervention groups
Copy and paste table for each intervention and comparison group
Intervention Group 1
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name HFNC
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(Continued)
No. randomized to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
Comparison Group 1
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name Invasive Ventilation
No. randomized to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
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(Continued)
Timing (e.g. frequency, duration of each
episode)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
Comparison Group 2
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name Non-Invasive Ventilation
No. randomized to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
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(Continued)
Notes:
7. Outcomes
Copy and paste table for each outcome.
Outcome 1
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Hospital Mortality
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
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(Continued)
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 2
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Intubation Rate
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
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(Continued)
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 3
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Treatment Faiulre- escalation to
other form of respiratory support
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
17High flow nasal cannula therapy for respiratory support in children (Protocol)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 4
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Duration of respiratory support
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
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(Continued)
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 5
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Complications- air leak, nasal
trauma, nosocomial sepsis, baro-
trauma, gastrointestinal distention
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
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(Continued)
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 6
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Length of Hospital stay
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
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(Continued)
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 7
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Clinical severity score
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
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(Continued)
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 8- secondary outcome
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Length of PICU stay
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
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(Continued)
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
8. Results
Copy and paste the appropriate table for each outcome, including additional tables for each time point and subgroup as required.
Dichotomous outcome
Outcome HFNC Invasive Ventilation Non Invasive Ventilation Details
No. with
event
No. without
event
No. with
event
No. without
event
No. with
event
No. without
event
Intubation
Failure of
Treatment
Hospital Mor-
tality
Complica-
tions
Continuous outcome
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Out-
come
Unit of
Mea-
sure-
ment
HFNC Group Invasive Ventilation
Group
Non Invasive
Group
Details
n M SD n M SD n M SD
Length
of PICU
stay
Clinical
Severity
Score
Dura-
tion of
Respira-
tory sup-
port
LOS-
Hospital
9. Applicability
Have important populations been ex-
cluded from the study? (consider disadvan-
taged populations, and possible differences in
the intervention effect)
Yes No Unclear
Is the intervention likely to be aimed at
disadvantaged groups? (e.g. .lower socioe-
conomic groups)
Yes No Unclear
Does the study directly address the re-
view question?
(any issues of partial or indirect applicability)
Yes No Unclear
Notes:
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10.Other information
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Key conclusions of study authors
References to other relevant studies
Correspondence required for further
study information (from whom, what and
when)
Notes:
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